{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:00:55Z","timestamp":1781020855888,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.chest.2025.12.032","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:12:57Z","timestamp":1780996377000},"page":"e175-e179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine"],"prefix":"10.1016","volume":"169","author":[{"given":"Kimberly","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia M.","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Murinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Buber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4221","authenticated-orcid":false,"given":"Samuel G.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2025.12.032_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1152\/ajplung.00356.2002","article-title":"Targeted blocking of gene expression for CGRP receptors elevates pulmonary artery pressure in hypoxic rats","volume":"285","author":"Ching","year":"2003","journal-title":"Am J Physiol Lung Cel Mol Physiol"},{"issue":"3 Pt 2","key":"10.1016\/j.chest.2025.12.032_bib2","doi-asserted-by":"crossref","first-page":"H681","DOI":"10.1152\/ajpheart.1992.263.3.H681","article-title":"CGRP and somatostatin modulate chronic hypoxic pulmonary hypertension","volume":"263","author":"Tjen-Looi","year":"1992","journal-title":"Am J Physiol Hear Circ Physiol"},{"issue":"8","key":"10.1016\/j.chest.2025.12.032_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.CIR.101.8.923","article-title":"In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse","volume":"101","author":"Champion","year":"2000","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2025.12.032_bib4","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.athoracsur.2007.03.067","article-title":"Effect of prepro-calcitonin gene-related peptide-expressing endothelial progenitor cells on pulmonary hypertension","volume":"84","author":"Zhao","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.chest.2025.12.032_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/clpt.2011.246","article-title":"A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina","volume":"91","author":"Chaitman","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.chest.2025.12.032_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/head.13316","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina","volume":"58","author":"Depre","year":"2018","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.chest.2025.12.032_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.arbres.2025.07.023","article-title":"A possible association between galcanezumab and pulmonary arterial hypertension","volume":"62","author":"Cruz-Utrilla","year":"2025","journal-title":"Arch Bronconeumol"},{"issue":"4","key":"10.1016\/j.chest.2025.12.032_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"issue":"38","key":"10.1016\/j.chest.2025.12.032_bib9","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.chest.2025.12.032_bib10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1152\/physrev.00037.2003","article-title":"Vascular actions of calcitonin gene-related peptide and adrenomedullin","volume":"84","author":"Brain","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.chest.2025.12.032_bib11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3389\/fphys.2018.01167","article-title":"The regulation of pulmonary vascular tone by neuropeptides and the implications for pulmonary hypertension","volume":"9","author":"Lo","year":"2018","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.chest.2025.12.032_bib12","first-page":"H277","article-title":"Calcitonin gene-related peptide increases pulmonary blood flow in fetal sheep","volume":"274","author":"De Vroomen","year":"1998","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1016\/j.chest.2025.12.032_bib13","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1152\/jappl.1989.67.3.1265","article-title":"Calcitonin gene-related peptide vasodilation of human pulmonary vessels","volume":"67","author":"McCormack","year":"1989","journal-title":"J Appl Physiol"},{"issue":"1","key":"10.1016\/j.chest.2025.12.032_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0735-1097(91)90729-S","article-title":"Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure","volume":"17","author":"Anand","year":"1991","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2025.12.032_bib15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1183\/09031936.02.01762002","article-title":"BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives","volume":"20","author":"Humbert","year":"2002","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2025.12.032_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension Study Group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2025.12.032_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00104807","article-title":"Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases","volume":"31","author":"Souza","year":"2008","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2025.12.032_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14740338.2023.2250720","article-title":"Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database","volume":"23","author":"Wang","year":"2024","journal-title":"Expert Opin Drug Saf"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:22:56Z","timestamp":1781018576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0012369226000036"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.032","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Arterial Hypertension Associated With Calcitonin Gene-Related Peptide Antagonist Therapy for Migraine","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2025.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}